MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

  • Ashkavandi, Zohreh Jaafari (Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Najvani, Ali Dehghani (Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Tadbir, Azadeh Andishe (Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Pardis, Soheil (Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Ranjbar, Mohammad Ali (Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Ashraf, Mohammad Javad (Department of Pathology, Medical School, Shiraz University of Medical Sciences)
  • Published : 2013.06.30


Background: Proliferation markers widely have been used to diagnose and determine the behaviour and prognosis of benign and malignant tumours. Minichromosome maintenance 3 (MCM3) is a novel proliferation marker. The aim of this study was to evaluate and compare MCM3 with Ki-67 in diagnosis of salivary gland tumours. Materials and Methods: In this retrospective study, immunohistochemical expression of MCM3 and Ki-67 was evaluated in 15 pleomorphic adenomas (PA), 17 mucoepidermoid carcinomas (MEC) and 18 adenoid cystic carcinomas (ADCC). Labeling indices (LIs) for the two markers were calculated and compared. Results: MCM3 and Ki-67 LIs were significantly higher in MEC and ADCC compared to PA. The LI of MCM3 was significantly higher than that of Ki-67 in MEC and PA. There was no significant difference between the two markers in ADCC. A cut-off point of 8% with 74.3% sensitivity and 93.3% specificity for MCM3 was obtained to discern between benign and malignant tumors. Conclusions: These results suggest that MCM3 might be a useful proliferation marker for differential diagnosis and recognition of clinical behavior of salivary gland tumors.


Supported by : Vice-Chancellery of Shiraz University of Medical Science


  1. Agarwal JP, Jain S,Gupta T, et al (2008). Intraoral adenoid cystic carcinoma: prognostic factors and outcome. Oral Oncol, 44, 986-93.
  2. Alison MR, Hunt T, Forbes SJ (2002). Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut, 50, 290-1.
  3. Brown DC, Gatter KC (2002). Ki67 protein: the immaculate deception? Histopathol, 40, 2-11.
  4. Chevalier S, Blow JJ (1996). Cell cycle control of replication initiation in eukaryotes. Curr Opin Cell Biol, 8, 815-21.
  5. Constantinos G, Stephanie V, Philippe V, Stamatios T (2010). MCM proteins as diagnostic and prognostic tumor marker in the clinical setting. Histol Histopathol, 25, 351-70.
  6. de Andrade BA, Leon JE, Carlos R, et al (2012). Expression of minichromosome maintenance 2, Ki-67, and geminin in oral nevi and melanoma. Ann Diag Pathol, 17, 32-6.
  7. Forsburg SL (2004). Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev, 68, 109-31.
  8. Freeman A, Morris LS, Mills AD, et al (1999). Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res, 5, 2121-32.
  9. Ghazy SE, Helmy IM, Baghdadi HM (2011). Maspin and MCM2 immunoprofiling in salivary gland carcinomas. Diagn Pathol, 6, 89.
  10. Gonzalez MA, Pinder SE, Callagy G, et al (2003). Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol, 21, 4306-13.
  11. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA (2005). Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg, 34, 533-6.
  12. Kodani I, Shomori K, Osaki M, et al (2001). Expression of minichromosome maintenance 2(MCM2), Ki-67,and cell-cycle- related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology, 69, 150-8.
  13. Korkolopoulou P, Givalos N, Saetta A, et al (2005). Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol, 36, 899-907.
  14. Li J, Deng M, Wei Q, Liu T, et al (2011). Phosphorylation of MCM3 protein by cyclin E/cyclin-dependent kinase 2 (Cdk2) regulates its function in cell cycle. J Biol Chem, 46, 39776-85.
  15. Mac Callum DE, Hall PA (2000). The location of PKI67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol, 190, 537-44.<537::AID-PATH577>3.0.CO;2-W
  16. Meng MV, Grossfeld GD, Williams GH, et al (2001). Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res, 7, 2712-8.
  17. Liu M, Li JS, Tian DP, et al (2013). MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer. Histol Histopathol, 28, 481-92.
  18. Nagao T, Sato E, Inoue R, et al (2012). Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem, 45, 269-82.
  19. Nurhan G, Nil C, Fatih C (2012). Ki-67 and MCM-2 in dental follicle and odontogenic cysts: the effects of inflammation on proliferative markers. Sci World J, [Epub ahead of print].
  20. Pich A, Chiusa L, Navone R (2004). Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol, 15, 1319-29.
  21. Speight P, Barrett A (2004). Salivary gland tumors. Oral Dis, 8, 229-40.
  22. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, et al (2006). Jelen M, Matkowski R, Pomiencko A, et al. MCM-2 protein expression predicts prognosid better than ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Ref, 26, 2473-8.
  23. Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pas J Cancer Prev, 13, 5155-9.
  24. Van Diest PJ, vander Wall E, Baak JP (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 57, 675-81.
  25. Van Oijen MG, Medema RH, Slootweg PJ, Rijksen G (1998). Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol, 110, 24-31.
  26. Vargas P, Cheng W, Barrett A, Craig G, Speight P (2008). Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumors. J Oral Pathol Med, 37, 309-18.
  27. Yang C, Wen Y, Li H, et al (2011). Overexpression of minichro mosome maintenance 2 predicts poor prognosis in patients with gastric cancer. Oncol Rep, 27, 135-42
  28. Youn SL, Seon-Ah Ha, Hae JK, et al (2010). Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol, 88, 138-42.

Cited by

  1. Influence of Ribosomal Protein L39-L in the Drug Resistance Mechanisms of Lacrimal Gland Adenoid Cystic Carcinoma Cells vol.15, pp.12, 2014,
  2. Ten Year Experience with Surgery and Radiation in the Management of Malignant Major Salivary Gland Tumors vol.15, pp.5, 2014,
  3. PGTools: A Software Suite for Proteogenomic Data Analysis and Visualization vol.14, pp.5, 2015,
  4. Caveolin-1 overexpression in benign and malignant salivary gland tumors vol.37, pp.2, 2016,
  5. The sonic hedgehog signaling pathway contributes to the development of salivary gland neoplasms regardless of perineural infiltration vol.37, pp.7, 2016,
  6. MCM3 pp.1541-2016, 2016,
  7. Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients vol.2018, pp.2314-6141, 2018,